Drugs / Miravirsen
Miravirsen
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01646489 | Jun → Sep 2012 | chronic hepatitis C virus infection | Santaris Pharma A/S | Completed | No outcome recorded |
| Phase 1 | NCT00688012 | May 2008 → May 2009 | hepatitis C virus infection | Santaris Pharma A/S | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01872936 | Jun 2013 → Jan 2015 | chronic hepatitis C virus infection | Santaris Pharma A/S | Unknown | No outcome recorded |
| Phase 2 | NCT01727934 | Nov 2012 → Jan 2014 | hepatitis C virus infection | Santaris Pharma A/S | Unknown | No outcome recorded |
| Phase 2 | NCT01200420 | Sep 2010 → Dec 2011 | chronic hepatitis C virus infection | Santaris Pharma A/S | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00979927 Comparator | Sep 2009 → Sep 2010 | hepatitis C virus infection | Santaris Pharma A/S | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Miravirsen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01646489 ↗ |
| Known as | Miravirsen sodium | “Drug: Miravirsen sodium” NCT01727934 ↗ |
| Known as | SPC3649 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00688012 ↗ |
| Action | Inhibit | “Miravirsen is a locked nucleic acid-modified DNA phosphorothioate antisense oligonucleotide that sequesters mature miR-122 in a highly stable heteroduplex, thereby inhibiting...” PMID 23534542 ↗ Mar 2013 |
| Modality | Antisense oligonucleotide | “Miravirsen is a locked nucleic acid-modified DNA phosphorothioate antisense oligonucleotide that sequesters mature miR-122 in a highly stable heteroduplex, thereby inhibiting...” PMID 23534542 ↗ Mar 2013 |
| Route | Subcutaneous | “The patients were randomly assigned to receive five weekly subcutaneous injections of miravirsen at doses of 3 mg, 5 mg, or 7 mg per kilogram of body weight or placebo over a...” PMID 23534542 ↗ Mar 2013 |